DOI QR코드

DOI QR Code

Lympho-Vascular Space Invasion Indicates Advanced Disease for Uterine Papillary Serous Tumors Arising from Polyps

  • Ilker, Selcuk (Gynecologic Oncology Unit, Zekai Tahir Burak Women's Health, Education and Research Hospital) ;
  • Elmas, Korkmaz (Gynecologic Oncology Unit, Zekai Tahir Burak Women's Health, Education and Research Hospital) ;
  • Emre, Ozgu (Gynecologic Oncology Unit, Zekai Tahir Burak Women's Health, Education and Research Hospital) ;
  • Mengu, Turker (Pathology Unit, Zekai Tahir Burak Women's Health, Education and Research Hospital) ;
  • Erkaya, Salim (Obstetrics and Gynecology, Hitit University, Faculty of Medicine, Corum, Turkey and Gynecologic Oncology Unit, Zekai Tahir Burak Women's Health, Education and Research Hospital) ;
  • Tayfun, Gungor (Department of Obstetrics and Gynecology, Hitit University, Faculty of Medicine, Corum, Turkey and Gynecologic Oncology Unit, Zekai Tahir Burak Women's Health, Education and Research Hospital)
  • Published : 2015.06.03

Abstract

Background: Uterine papillary serous tumors are rarely seen and behave aggressively. Our aim was to evaluate uterine papillary serous tumors arising from polyps. Materials and Methods: Clinicopathological data of patients with uterine serous cancer arising from a polyp at the Gynecological Oncology Department of Zekai Tahir Burak Women's Health Education and Research Hospital were reviewed retrospectively. Results: We analyzed patients according to FIGO 2009 staging system as stage 1A and higher than stage 1A (3 and 6, respectively). All the patients were postmenopausal. Mean CA-125, CA-19.9 and CA15.3 levels were elevated in higher than stage 1A group. However we did not find a statistical difference between age, parity, polyp size, CA-125, CA-15.3, CA-19.9 and CEA levels. Lympho-vascular space invasion (LVSI) showed predictivity for advanced disease (p=0.025). Conclusions: The histopathologic nature of uterine serous carcinoma is a unique entity. LVSI is a prognosticator for defining an advanced stage uterine papillary tumor.

Keywords

References

  1. Bokhman JV (1983). Two pathogenetic types of endometrial carcinoma. Gynecol Oncol, 15, 10-7. https://doi.org/10.1016/0090-8258(83)90111-7
  2. Carcangiu ML, Tan LK, Chambers JT (1997). Stage IA uterine serous carcinoma: a study of 13 cases. Am J Surg Pathol, 21, 1507-14. https://doi.org/10.1097/00000478-199712000-00015
  3. Cirisano FD, Jr., Robboy SJ, Dodge RK, et al (1999). Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol, 74, 385-94. https://doi.org/10.1006/gyno.1999.5505
  4. del Carmen MG, Birrer M, Schorge JO (2012). Uterine papillary serous cancer: a review of the literature. Gynecol Oncol, 127, 651-61. https://doi.org/10.1016/j.ygyno.2012.09.012
  5. Demiral S, Beyzadeoglu M, Sager O, et al (2014). Evaluation of treatment outcomes of early-stage endometrial cancer radiotherapy: a single center experience. Asian Pac J Cancer Prev, 15, 9599-602. https://doi.org/10.7314/APJCP.2014.15.22.9599
  6. Desai NB, Kiess AP, Kollmeier MA, et al (2013). Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy. Gynecol Oncol, 131, 604-8. https://doi.org/10.1016/j.ygyno.2013.09.019
  7. Geisler JP, Geisler HE, Melton ME, et al (1999). What staging surgery should be performed on patients with uterine papillary serous carcinoma? Gynecol Oncol, 74, 465-7. https://doi.org/10.1006/gyno.1999.5513
  8. Giordano G, Gnetti L, Merisio C, et al (2007). Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps. Maturitas, 56, 190-7. https://doi.org/10.1016/j.maturitas.2006.08.002
  9. Goff BA, Kato D, Schmidt RA, et al (1994). Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol, 54, 264-8. https://doi.org/10.1006/gyno.1994.1208
  10. Hendrickson M, Ross J, Eifel P, et al (1982). Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol, 6, 93-108. https://doi.org/10.1097/00000478-198203000-00002
  11. Huh WK, Powell M, Leath CA, et al (2003). Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol, 91, 470-5. https://doi.org/10.1016/j.ygyno.2003.08.027
  12. Idrees R, Din NU, Fatima S, et al (2013). Serous carcinoma arising in endometrial polyps: clinicopathologic study of 4 cases. Ann Diagn Pathol, 17, 256-8. https://doi.org/10.1016/j.anndiagpath.2012.11.003
  13. Moore KN, Fader AN (2011). Uterine papillary serous carcinoma. Clin Obstet Gynecol, 54, 278-91. https://doi.org/10.1097/GRF.0b013e318218c755
  14. Nugent EK, Bishop EA, Mathews CA, et al (2012). Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma? Gynecol Oncol, 125, 94-8. https://doi.org/10.1016/j.ygyno.2011.11.049
  15. Oz M, Ozgu E, Korkmaz E, et al (2014). Utility of frozen section pathology with endometrial pre-malignant lesions. Asian Pac J Cancer Prev, 15, 6053-7. https://doi.org/10.7314/APJCP.2014.15.15.6053
  16. Rauh-Hain JA, Growdon WB, Schorge JO, et al (2010). Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma. Gynecol Oncol, 119, 299-304. https://doi.org/10.1016/j.ygyno.2010.07.010
  17. Savelli L, De Iaco P, Santini D, et al (2003). Histopathologic features and risk factors for benignity, hyperplasia, and cancer in endometrial polyps. Am J Obstet Gynecol, 188, 927-31. https://doi.org/10.1067/mob.2003.247
  18. Sethasathien P, Charoenkwan K, Siriaunkgul S (2014). Accuracy of intraoperative gross examination of myometrial invasion in stage I-II endometrial cancer. Asian Pac J Cancer Prev, 15, 7061-4. https://doi.org/10.7314/APJCP.2014.15.17.7061
  19. Sherman ME, Bitterman P, Rosenshein NB, et al (1992). Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol, 16, 600-10. https://doi.org/10.1097/00000478-199206000-00008
  20. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  21. Silva EG, Jenkins R (1990). Serous carcinoma in endometrial polyps. Mod Pathol, 3, 120-8.
  22. Slomovitz BM, Burke TW, Eifel PJ, et al (2003). Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol, 91, 463-9. https://doi.org/10.1016/j.ygyno.2003.08.018
  23. Wheeler DT, Bell KA, Kurman RJ, et al (2000). Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol, 24, 797-806. https://doi.org/10.1097/00000478-200006000-00004

Cited by

  1. Adjuvant Pelvic Radiation “Sandwiched” Between Paclitaxel/Carboplatin Chemotherapy in Women With Completely Resected Uterine Serous Carcinoma pp.1048-891X, 2018, https://doi.org/10.1097/IGC.0000000000001359
  2. Malignant Endometrial Polyps in Uterine Serous Carcinoma: The Prognostic Value of Polyp Size and Lymphovascular Invasion vol.28, pp.3, 2018, https://doi.org/10.1097/IGC.0000000000001213